YH 4808

Drug Profile

YH 4808

Alternative Names: YH-4808

Latest Information Update: 08 Sep 2015

Price : $50

At a glance

  • Originator Yuhan
  • Class Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastro-oesophageal reflux; Reflux oesophagitis
  • Discontinued NSAID-induced ulcer

Most Recent Events

  • 08 Sep 2015 Discontinued - Phase-II for NSAID-induced ulcer in South Korea (PO)
  • 08 Sep 2015 No recent reports on development identified - Phase-I for Gastro-oesophageal reflux (In volunteers) in USA (PO)
  • 08 Sep 2015 YH 4808 is still in phase II trials for Gastro-oesophageal reflux in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top